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In this review article we consider results suggesting that transmission of 
human cytomegalovirus (HCMV) from a donor of a solid organ to an 
immunologically naive individual can be reduced. Two randomised controlled 
trials have been conducted recently, one of active immunisation of recipients 
pre-transplant and another of passive immunisation with monoclonal 
antibodies specific for HCMV given at the time of transplant. Although the 
available data are encouraging – providing evidence of a reduction in the 
incidence of HCMV viraemia - they fall short of what would be required to 
prove definitively that transmission has been completely prevented. Here we 
reflect on these studies and propose a set of five criteria which, if satisfied in 
the future, could be taken as proof that active and/or passive immunisation 
against HCMV effectively interrupts transmission of virus from the donor. We 






AUC- Area Under the Curve 
Cmax- maximum concentration (in serum) 
D- Donor 
gH- glycoprotein-H 
mAbs- monoclonal antibodies 
PK- Pharmacokinetics 
R- Recipient 
SOT- Solid Organ Transplant 
t1/2- Elimination half-life 
Tmax- Time at which drug concentration is maximal 





Human cytomegalovirus (HCMV) is an important opportunistic pathogen in 
patients undergoing solid organ transplantation (SOT). The natural history of 
HCMV infection in these patients is complex (1). Recipients who have HCMV-
specific IgG antibodies before transplant (seropositives; R+) are at risk of 
reactivating virus once they receive immunosuppressive drugs. They are also 
at risk of reinfection if a different strain of HCMV is transferred from a 
seropositive donor organ (D+). Recipients who are seronegative (R-) may 
also acquire primary infection from a seropositive donor organ (1, 2). After 
transmission, viral replication in the recipient leads to the appearance of 
HCMV DNA in the blood (viraemia) reflecting an increased potential to 
disseminate HCMV causing a variety of end-organ diseases which is directly 
related to higher viral loads (2, 3). The ability of HCMV to reactivate from 
latency and reinfect seropositive individuals, along with the threat of primary 
infection means the risk of infection is so high, and the risk of disease so 
serious, that transplant centres routinely employ one of two strategies to use 
ganciclovir or its oral prodrug valganciclovir to prevent HCMV end-organ 
disease (4).  
 
For the strategy of prophylaxis, patients are given drug from the time of 
transplant onwards for a fixed period of time, with clinical trials supporting 
duration of prophylaxis of 100 days or 200 days (5, 6). This strategy 
effectively prevents end-organ disease for these periods of time, but patients 
remain at risk of developing viraemia and late onset disease once prophylaxis 
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is stopped (7). This is a particular problem in the high risk D+R- subgroup 
where a recipient without natural immunity receives an organ from a 
seropositive donor (7). In some cases, late onset disease is caused by strains 
of HCMV that have developed resistance to ganciclovir which requires the use 
of increasingly toxic second line therapies (8, 9). 
 
For the strategy of pre-emptive therapy, no patient receives prophylaxis and 
drug is only administered to those where surveillance samples detect viraemia 
above a threshold value defined by real time polymerase chain reaction 
(PCR) (2). Pre-emptive therapy is typically stopped when a patient has two 
consecutive blood samples where HCMV DNA is undetectable (2). 
Surveillance for infection continues and some patients develop a second 
episode of viraemia which is again treated until viraemia becomes 
undetectable. Thus one clear advantage of this approach is the administration 
of a toxic drug in limited doses to a subset of patients at highest risk of HCMV 
disease. Occasional patients develop resistant strains of HCMV (10). 
 
These two strategies are equally effective at preventing end-organ disease as 
shown by a meta-analysis by the Cochrane collaboration of the seven 
controlled trials that have randomised SOT patients to be managed by either 
prophylaxis or pre-emptive therapy (11). As a consequence, both strategies 
are recommended in clinical guidelines as suitable ways of preventing HCMV 
end-organ disease (4). However, they have different characteristics such that 
some centres prefer one strategy over the other. For example, prophylaxis 
may be preferred where patients are discharged from a transplant centre for 
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continuing care to a small, distant hospital that does not have access to PCR 
diagnosis. 
 
Pertinent for our own studies, pre-emptive therapy has the considerable 
advantage that it provides information about the natural history of HCMV 
infection in individual patients prior to therapeutic intervention. The duration of 
viraemia, the duration of treatment and the peak viral load represent important 
biomarkers that can be used to assess the ability of cohorts of patients to 
control HCMV replication (2). Highest values of all three parameters are found 
in D+R- patients, intermediate values in D+R+ patients and lowest values in 
D-R+ patients, paralleling the respective risks for HCMV end-organ disease 
associated with primary infection, reinfection and/or reactivation and 
reactivation respectively in solid organ transplant patients (2, 3). The values 
seen in the 3 patient groups are highly significantly different, but we 
emphasise that there is substantial overlap so that the viral load results in a 
single individual cannot distinguish between primary infection, reinfection or 
reactivation.(2)  The availability of these rigorously defined biomarkers allows 
clinical trials to be designed so that the values can be used as 
pharmacodynamic assessments of whether or not prototype HCMV 
immunological interventions given pre-transplant or peri-transplant can control 
the extent of virus replication post-transplant. Three randomised controlled 
trials have been conducted to date as reviewed below. 




In 1984, a single dose of a live attenuated vaccine based on the Towne strain 
of HCMV was given to seronegative and seropositive candidates awaiting 
renal transplantation (12). This vaccine did not reduce the incidence of HCMV 
infection or the incidence of HCMV end-organ disease after transplant (table 
1A). However, it appeared to reduce the severity of disease although the 
Phase 2 clinical trial was not powered to provide statistical significance in 
selected subsets of patients (table 1B and figure 1). In light of our current 
understanding of the pharmacodynamics of HCMV in these patients, we 
would interpret these results as the vaccine reducing the peak viral load and 
its associated risk for disease, but PCR, and quantitative measures of HCMV 
viraemia, were not available at that time. However, it is clear from the study 
that the vaccination strategy did not interrupt transmission of HCMV, so how 
did it influence severity of disease? When peak viraemia is plotted against risk 
of end-organ disease, a sigmoid curve is obtained (13, 14). The fact that both 
groups developed end-organ disease suggests that they both crossed this 
threshold value allowing the virus to disseminate to those organs. It is not 
known if receipt of an even higher dose of virus could increase the severity of 
disease, but this is one possible explanation for the benefit produced by the 
Towne vaccine; that is, it reduced the effective inoculum. Alternatively, both 
groups of patients may have received the same dose of virus, but the 
recipients of Towne vaccine were better able to control virus replication, 
because their immune systems had been primed, so limiting the severity of 




In 2011, a vaccine comprising soluble recombinant glycoprotein B (gB) 
together with MF59 adjuvant was given to seronegative and seropositive 
candidates awaiting transplantation of a kidney or a liver (15). The rationale 
for this choice of immunogen is that gB is an important structural determinant 
of virus entry into cells and represents a major target of the humoral response 
against HCMV in healthy seropositives. Importantly, when compared to 
placebo recipients, the vaccine appeared to reduce key markers of viral load 
post-transplant (15). Again, this Phase 2 study was not powered to provide 
statistical significance in subsets of patients, but the apparent rate of 
transmission of HCMV from donor to recipient was reduced (table 2). The titre 
of antibodies induced by the vaccine was reported as a correlate of protection, 
because it was significantly inversely associated with the duration of viraemia 
(15). The numbers of patients in subgroups are limited, but the fact that there 
was no apparent effect on reactivation but the biomakers in those at risk of 
either reactivation or reinfection were lower, suggested that reinfection was 
reduced in the D+R+ subgroup (table 2). This potential explanation of reduced 
exogenous infection was seen even more clearly in the D+R- subgroup at risk 
of primary infection (table 2). Thus, the gB/MF59 vaccine used in this study 
may have interrupted transmission of HCMV from the donor to both 
seronegative and seropositive recipients. 
 
This observation that humoral immune responses against HCMV might be 
protective in transplant recipients, led one of us (PDG) to propose a clinical 
trial to Genentech in 2013. The possibility that preformed antibodies present 
at the time of transplant could reduce transmission of HCMV from the donor 
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organ could be evaluated in a randomised controlled trial comparing placebo 
with the infusion of monoclonal antibodies (mAbs) with activity against HCMV. 
Clinical grade antibodies against gB were not available and so the study was 
conducted with two different mAbs; one directed against glycoprotein H (gH), 
another essential protein of the HCMV entry machinery, and one against the 
protein product of HCMV gene UL131 which is one component of the 
pentameric complex that is necessary to mediate entry of HCMV into 
epithelial and endothelial cells (16). Seronegative recipients about to receive 
kidneys from seropositive donors received either the combination of both 
mAbs or a matching placebo. Genentech organised and conducted a 
multicentre, multinational randomised controlled trial to recruit 120 patients 
and published the results in 2017 (17). These results were consistent with the 
hypothesis that humoral immunity can prevent transmission of HCMV from the 
donor organ to cause clinically significant HCMV viraemia in the post-
transplant period (table 3). In addition, the study reported significantly reduced 
CMV syndrome in the recipients of the mAbs (17). 
An important conclusion from this application of passive immunity is that 
measurements of concentrations of mAbs found in recipients inform the target 
level that active immunisation with the relevant antigen should also aim to 
achieve. The values are plotted but not reported in the supplementary 
material of the paper describing the clinical trial but can be inferred from the 
earlier Phase 1 study that gave the same dose (10mg/Kg each) of the same 
mAbs to normal volunteers (table 4A and 4B) (17, 18). The half-life was given 
as 26.9 and 27.4 days in the renal transplant recipients, which is very similar 
to the values in tables 4A and 4B. Thus, the pharmacokinetic parameters 
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shown in table 4A and 4B provide direct values of antibody concentrations 
against gH and UL131 that are associated with protection from acquisition of 
HCMV. Future Phase 1 clinical studies could use increasing doses of antigens 
together with a compatible adjuvant to produce a polyclonal response in 
volunteers that is biologically equivalent to these concentrations of mAbs as a 
way of prioritising doses to be taken forward into challenge studies in 
transplant patients. Thus, an iterative cycle of Phase 2 pharmacodynamics of 
active immunisation in D+R- allograft patients with identification of a humoral 
correlate of immunity, identification of clinical grade mAbs for placebo-
controlled interruption of transmission of donor virus followed by Phase 1 
selection of a corresponding immunogen could provide a pathway for 
development of a protective vaccine candidate to be evaluated in a Phase 3 
definitive study. 
This study of passive immunity administered the mAbs at the time of 
transplant and on three occasions post transplant (17). Future studies could 
compare reduced numbers of administrations to address the question of how 
long a donated organ remains potentially infectious for a seronegative 
recipient. We have reported from highly selected anecdotal cases that an 
organ dwell time of 28 hours is sufficient to transmit CMV from a seropositive 
donor, but no studies have evaluated how long the risk continues for post-




Suggested criteria to evaluate whether active or passive 
immunisation can completely or partially interrupt transmission of 
HCMV from the donor. 
 
It is plausible that these latter two studies interrupted transmission of HCMV, 
but the data available fall short of what would be required to substantiate this. 
One problem is that, although the D+R- transplant combination represents a 
human challenge model, the rate of transmission is less than 100%, with 
figures of 70% and 88% for renal and liver transplants respectively in our 
institution and 70% for the renal transplants in the multicentre study of mAbs 
(2, 17). This aspect introduces an element of uncertainty regarding 
transmission and introduces a second problem: the number of individuals in a 
typical Phase 2 clinical trial is small, so limiting robust analyses of subgroups. 
While these caveats hinder effective retrospective analyses of previous 
studies there are, currently, a series of HCMV vaccines in various stages of 
clinical evaluation and some may be studied in the SOT setting (20). We 
propose that the novel possibility of interrupting transmission of HCMV should 
be examined in all future studies of active and passive immunisation against 
HCMV and suggest the following 5 criteria for assessment: 
 





Before PCR became available, surveillance samples of urine and saliva were 
collected from transplant recipients and tested by conventional cell culture or 
rapid cell culture confirmation methods to detect HCMV (21). The sensitivity 
for predicting future HCMV end-organ disease was good, but the positive 
predictive value was low, because most people with HCMV in the urine or 
saliva did not develop and-organ disease (21). The same was true when urine 
and saliva samples were tested by PCR (22). Methods based on PCR were 
able to detect the lower levels of HCMV found in blood and had a better 
positive predictive value than either urine or saliva and so replaced these 
earlier diagnostic methods (2, 22). 
However, in the modern era, detection of HCMV in saliva and urine could be 
used as sensitive methods of identifying active infection in the salivary glands 
and kidneys respectively. The observation of serial negative PCR results from 
saliva and urine in an individual patient would then support the conclusion that 
HCMV had not been transmitted from the donor. 
In our hands, the results of following hundreds of D-R- transplant patients for 
evidence of viraemia consistently show an absence of infection (2). Thus, 
serial negative PCR tests from D-R- transplants show a very low probability of 
recipients acquiring HCMV infection unrelated to their transplant. 
Nevertheless, the power of sequencing could be harnessed to address the 
potential confounder that a community acquired primary infection could occur 
long after transplant (rather than from the donor organ). A sequencing 
approach would facilitate a direct comparison of the recipient strains of HCMV 




2. Serological responses to antigens not contained in the vaccine being 
evaluated. 
 
Patients given active or passive immunisation would be expected to have 
detectable levels of antibodies reactive with the antigen used in the vaccine or 
the antigen reactive with any mAbs given passively. However, patients would 
only be expected to possess antibodies against other HCMV antigens if they 
had become actively infected. 
There are several ways in which antibodies can be detected against HCMV 
antigens and differentiated from those present in the vaccine. For example, 
Pass et al absorbed sera with gB before performing standard enzyme 
immunoassay for IgG when evaluating the gB/MF59 vaccine in seronegative 
women (23). Alternatively, derivations of western blot assays could be used to 
detect antibodies of defined antigenic specificity and a number of commercial 
kits apply this to diagnostic tests for HCMV infection – including the 
identification of different isotype responses. In the same way, enzyme 
immunoassays could be developed to detect HCMV individual antigens not 
present in a particular vaccine. 
Clearly, this approach would not be applicable for vaccines based on whole 
HCMV, such as live attenuated strains. However, manufacturers should 
consider deleting one or more genes from HCMV that are neither essential for 
replication nor for protective immunity as a way of facilitating serological 




3. Evidence of T cell responses to antigens not contained in the vaccine 
being evaluated. 
 
Following natural infection, all proteins of HCMV are recognised by the 
cellular arm of the immune system. A herculean analysis by Sylwester et al 
demonstrated that the T cell response is large and varied against multiple 
antigens (24). Thus the detection of T cell responses specific for HCMV in 
patients given a vaccine that induces humoral immunity alone, or given 
infusions of mAbs, would show that recipients have immunological experience 
of antigens independent of those contained in the vaccine. 
If the vaccine was designed or known to induce T cell responses, then assays 
with specificity for antigens not present in the vaccine would have to be used; 
again this would require manufacturers of attenuated vaccines to delete non-
essential genes. 
 
4. Evidence of HCMV latency in recipients. 
 
A key biological characteristic of HCMV is the establishment of latency and 
would represent a clear marker of transmission from a donor to a seonegative 
recipient. Long term follow up of patients post-transplant could include an 
analysis for viral latency in individuals without viraemia. Isolation of 
monocytes from peripheral blood would allow a simple analysis for the 
presence of viral DNA and also a viral transcript landscape consistent with 
latent infection (25, 26).  
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True latency is defined by the capacity of the virus to reactivate which can be 
done using in vitro stimulation of monocytes, although this would represent an 
attractive additional analysis rather than a mandatory one (25, 27). Again the 
power of sequencing could be harnessed whereby a clear demonstration that 
the recipient strain matched that of the donor would strongly support 
transmission from a seropositive donor. 
Conversely, repeatedly negative samples from a recipient would be consistent 
with the possibility that transmission of donor virus had been successfully 
prevented. 
5. Evidence of effects on long term NK cell repertoire. 
 
Another aspect would utilise the apparent immunological imprinting 
associated with HCMV infection. Classically, NK cells were considered to be a 
part of the innate immune system, some recent publications demonstrate that 
NK cells undergo preferential clonal expansion following HCMV infection.(28, 
29) Therefore, NK cells from HCMV infected individuals possess different 
subsets of memory-like NK cells. This clonal-like expansion of NK cells in 
response to HCMV infection shapes and alters the NK cell receptor repertoire 
in multiple ways: i) expanding an NK cell subset expressing the activating 
CD94/NKG2C receptor (29) ii) causing stable imprints in the human KIR 
repertoire which is skewed towards a bias for self-specific inhibitory KIRs(30); 
iii)  driving the expression of the immune evasion genes of HCMV, many of 
which affect display of HLA class I molecules (31). The memory-like NK cell 
repertoire is presumably modulated and maintained by mechanisms that rely 
on both epigenetic modification of gene expression and antibody-dependent 
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expansion.(30, 32, 33) The presence of so called “memory-like” NK cells in 
the infected individuals argues that immunological responsiveness of these 
cells could be different to the NK cells from uninfected subjects. If this change 
in NK phenotype were seen in transplant recipients, it would provide evidence 
that HCMV infection was established in the recipient and so implicate 
transmission of virus from the donor. In contrast, if no such changes in NK 
phenotype were seen, it would add further support for the conclusion that the 
recipient had resisted transmission of HCMV from the donor. A single recent 
publication reports that significant changes in NK phenotype can be seen from 
6 months post transplant in patients with primary CMV infection.(34).
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Practical considerations for study design 
 
It is clear that there are several practical implications if these concepts are to 
be incorporated into the design of the next set of studies of active and passive 
immunisation against HCMV. These include: 
 Donor samples should be collected where possible pre-transplant, e.g. 
in live-related organ transplant to allow a genetic characterisation of 
this virus 
 Urine and saliva as well as blood should be collected at every post-
transplant visit to allow for monitoring of infection in different body 
compartments. 
 A follow-up component of the study should be incorporated, perhaps as 
a sub-study, to examine in detail those D+R- patients who do not have 
viraemia post-transplant. They should be followed to see if they 
seroconverted and have the tests discussed above applied. As a way 
of controlling costs, samples could be stored prospectively and only 
tested if likely to be informative. 
 
Why is this subject important? 
 
While the development of a vaccine that prevents overt disease in a number 
of clinical settings is paramount, it is highly desirable that any HCMV vaccine 
also interrupts transmission of virus. If administered to the general population, 
such a vaccine would have dramatic implications for young women of child 
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bearing age given the devastating consequences associated with congenital 
HCMV infection (35).  
 
The results have inherent scientific value as they will help to differentiate 
between complete interruption of transmission or merely reduction in the 
effective inoculum. A more complete understanding of the process that leads 
to transmission can only help the design of future studies that aim to inhibit it. 
Our current working hypothesis is that cells in the donor organ harbouring 
latent HCMV are stimulated by inflammation and cytokine storm at the time of 
transplantation to reactivate HCMV (D+) (36). Starting from only a small 
number of cells, HCMV infection proceeds to infect other cells, to spread from 
the local site of replication and then to cause viraemia (37, 38). The immune 
system may be able to contain this process at the site of transplant by 
attacking individual virions or infected cells before virions are released. We 
propose that the latter target is a more plausible way of explaining how pre-
formed antibodies could prevent transmission of infection from the donor to 
the recipient. The immunological mechanism responsible may therefore 
include processes like antibody dependent cellular cytotoxicity in addition to 
the more conventionally studied virus neutralisation if cell associated virus is 
to be targeted by the humoral antibody response plus innate NK immunity.  
 
The results may also reveal new correlates of protection and/or mechanistic 
correlates of protection (39). For example, the inverse relationship between 
the duration of viraemia and the titre of antibodies against gB identified these 
antibodies as a correlate of protection (15). However, the mechanistic 
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correlate might have been, for example, CD4 cells specific for HCMV with 
their contribution to T-help for B-cells explaining the correlation with protection 
seen for antibody titre. That said, the complementary randomised controlled 
trial of infusion of mAbs demonstrates that humoral immunity can be 
protective and likely elevates the titre of gB antibodies into the category of a 
mechanistic correlate of protection (17, 39). More direct support for gB 
antibody responses will require studies directly infusing mAbs against gB into 
recipients -the mAbs infused in the Genetech trial were not specific for gB but 
for components of two major complexes on the surface of the virion (gH and 
UL131) (17). We thus propose that any mAbs that recognise HCMV proteins 
displayed on the surface of infected cells should be considered candidates for 
clinical evaluation (40).  
 
The follow up studies proposed could also prove important to give advice to 
recipients who received an experimental vaccine and now require a second 
transplant. Do they have any long-term immunity against HCMV? Do they 
harbour latent HCMV and thus will they reactivate HCMV once given high-
dose immunosuppressive drugs like basiliximab that they are not currently 
receiving as maintenance immunosuppression? Will any immunity be 
sufficient to resist HCMV present in a new donor organ? Should they be given 
booster doses of the vaccine (if it is still available)? Answers to these 
questions would help transplant clinicians give accurate information and 




It is important to determine if patients who resisted HCMV challenge from an 
organ donor and subsequently have some evidence of HCMV (e.g. T cell 
responses) but, possibly, no evidence of latent infection, should be 
considered along with other "seropositives" in terms of assessing life 
expectancy. Studies to date report an approximate one year lowered median 
life expectancy from being HCMV seropositive with a relative hazard of 
approximately 1.2 for overall mortality after controlling for risk factors of 
diabetes, smoking and obesity (41, 42). It is currently unclear whether this 
effect is found in individuals with latent infection or whether reactivation(s) 
and/or reinfections are required in addition. If immunisation can be shown to 
maintain individuals in the low-risk "seronegative" category, then this would 
improve cost benefit analyses of vaccine strategies and candidates. 
 
Finally, an extension of these analyses will provide another parameter to allow 
pre-emptive therapy to be compared with prophylaxis. For example, we are 
not aware of any studies showing that prophylaxis prevents transmission of 
virus from the organ donor. Certainly, some recipients get viraemia when 
prophylaxis is stopped, so arguing that these individuals have been infected 
(7). However, if prophylaxis did impact on transmission then that could be 
assessed as a potential benefit. 
 
In conclusion, maximising our understanding from the clinical trials performed 
with current vaccine candidates has the potential to provide novel insight into 
the natural history of this virus alongside the clear implications for iterative 
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Table 1. Results from randomised; double blind, placebo controlled 
clinical trial with Towne strain human cytomegalovirus vaccine study.  
 
A) CMV illness and infection in 91 patients followed ≥6 months after transplant. 
B) Grouping of clinical scores in recipient-seronegative donor-seropositive 
group.  D(+)- donor HCMV seropositive, D(-)- donor HCMV seronegative, 
R(+)- recipient HCMV seropositive, R(-)- recipient HCMV seronegative. 
Assessment of severity of disease associated with CMV infection was made 
with an arbitrary scoring system: fever scored: 1-3 points, leukopenia: 1 point, 
thrombocytopenia: 1, hepatitis: 1-3, pneumonia: 1-3, central nervous system 
changes: 1-3, glomerulonephritis: 1-3, arthritis: 2, muscle wasting: 2, bacterial 
superinfection: 3, gastrointestinal haemorrhage: 3, and death: 4. To be scored, 
a febrile illness had to occur concomitantly with laboratory evidence of CMV 
infection (virus excretion or rise in antibody titre).  
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Figure 1. Clinical scores in recipient-seronegative donor-seropositive 
vaccine and placebo groups.  
The median values of clinical score for vaccine and placebo groups are 
represented by horizontal lines. Statistical difference- two-tailed p-value 
(0.0583) was obtained from the Mann-Whitney U test. 
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Table 2. Results from a randomized; double blind, placebo controlled 
clinical trial of recombinant soluble glycoprotein-B vaccine with MF-59 
adjuvant in solid organ transplant patients. 
Serial blood samples were tested for cytomegalovirus DNA by real-time 
quantitative PCR (rtqPCR). Viraemia was defined as a blood sample that was 
PCR positive (cutoff 200 genomes per mL whole blood). Any patient with one 
blood sample containing more than 3000 cytomegalovirus genomes per mL 
received ganciclovir until two consecutive undetectable cytomegalovirus DNA 
measurements.  
*Total number of person-days during which any participant had viraemia 
higher than 200 genomes per mL or received treatment divided by total 
number of days of follow-up for all participants who underwent a 
transplantation. The proportion of days of post-transplantation follow-up spent 
with viraemia (or receiving treatment) was calculated for each individual. 
These values were then compared between vaccine and placebo with a 
Mann-Whitney U test. Comparison of proportion of days of viraemia in (all) 
vaccine versus (all) placebo p=0·99.  
27 
 27 
Table 3. Results from a randomized, double-blind, placebo-controlled 
trial of RG7667.  
RG7667 is a combination of two monoclonal antibodies, one reactive with 
glycoprotein H and the second reactive with the protein from UL131. The 
proportion of patients with CMV viremia (viral load of ≥150 copies/ml) 
measured by quantitative PCR and the proportion of patients with CMV 
syndrome is shown for the follow-up period of 24 weeks post-transplant. 
CMV syndrome was defined as the presence of CMV in the blood and at least 
one of the following: fever, new or increased malaise, leukopenia, atypical 
lymphocytosis, or thrombocytopenia. End Organ CMV disease was defined as 
presence of CMV in the blood and at least one of the following: localized CMV 
infection confirmed in a biopsy or other specimen and relevant symptoms or 
signs of organ dysfunction unlikely to be due to other causes  
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Table 4. Pharmacokinetic parameters of passive immunisation study of 
RG7667 in normal healthy volunteers.  
RG7667 is the code name for two monoclonal antibodies MCMV5322A (a 
human, affinity-matured version of MSL-109 that recognizes CMV 
glycoprotein H (gH) and MCMV3068A (a humanized mouse monoclonal 
antibody that recognizes the protein encoded by UL131). A) Pharmacokinetic 
parameters of MCMV5322A (mAb gH); B) Pharmacokinetic parameters of 
MCMV3068A (mAb UL131). Pharmacokinetic parameters were 
measured at different occasions: 29 and 58 days following the administration 









D- R- 32 
Placebo(12) 1/12 (8) 1/12 (8) 
Vaccine (20) 0/20 (0) 0/20 (0) 
D- R+ 14 
Placebo (5) 2/5 (40) 0/5 (0) 
Vaccine (9) 3/9 (33) 1/9 (11) 
D+ R+ 15 
Placebo (7) 6/7 (86) 2/7 (29) 
Vaccine (8) 6/7 (86) 2/8 (25) 
D+ R- 30 
Placebo (14) 11/14 (79) 10/14 (70) 
Vaccine (16) 15/16 (94) 9/16 (56) 
Re-drawn from: Plotkin. Lancet, 1984. 323(8376): p.528-530. 
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Table 1B.  
D+R- 
Number with score 
0 1-6 ≥7 
Vaccine 7 9 1 
Placebo 4 4 7 
Re-drawn from: Plotkin. Lancet, 1984. 323(8376): p.528-530
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Table 2.  











D- R- 22 
Placebo(10) 0 0 0/915 (0) 0/915 (0) 
Vaccine (12) 0 0 0/1204 (0) 0/1204 (0) 
D- R+ 18 
Placebo (7) 2 0 2/696 (0.3) 0/696 (0) 
Vaccine (11) 4 0 21/1209 (1.7) 0/1209 (0) 
D+ R+ 22 
Placebo (15) 6 3 119/1489 (8.0) 135/1489 (9.1) 
Vaccine (7) 4 0 6/803 (0.7) 0/803 (0) 
D+ R- 16 
Placebo (5) 5 4 339/599 (56.6) 415/599 (69.3) 
Vaccine (11) 6 5 128/1069 (12.0) 142/1069 (13.3) 
Re-drawn from: Griffiths. Lancet, 2011. 377(9773): p. 1256-63. 
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Table 3.  
Parameter placebo MAb p value 
Viraemia 40/57 (70%) 30/59 (50.8%) 0.04 
Median days to viraemia 46 139 0.01 
CMV syndrome 16% 3% 0.03 
End-organ disease 4 0 n/a 




Selected PK of mAB gH at 10mg/kg in normals 
 Single dose d29 d57 
AUC μg.day/ml 3707 3865 4553 
Cmax μg /ml 277 253 340 
Tmax day 0.064 0.188 0.125 
t½ day ND ND 23.7 




Ishida. Antimicrbo Agents Chemother, 59, 4919-4929, 2015  
Selected PK of mAB UL131 at 10mg/kg in normals 
 Single dose d29 d57 
AUC μg.day/ml 5018 4838 4914 
Cmax μg /ml 351 441 356 
Tmax day 0.063 0.063 0.188 
t½ day 28.2 ND 29.0 
